12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Glycerol phenylbutyrate: Phase II data

Data from Part B of the double-blind, international Phase II HALT-HE trial in 178 patients with episodic HE showed that twice-daily 6 mL glycerol phenylbutyrate for 16 weeks met the primary endpoint of a lower proportion of patients who experienced >=1 HE event vs. placebo (21.1% vs. 36.4%, p=0.0214). The rate of adverse events was similar between treatment groups. Patients, which were required to have >=2 documented HE events in the 6 months...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >